Endoscopic surveillance of patients with Barrett's esophagus (BE) is inefficient. Risk stratification of patients might improve the effectiveness of surveillance. We performed a systematic review and meta-analysis to identify factors associated with progression of BE without dysplasia or BE with low-grade dysplasia (LGD) to high-grade dysplasia or esophageal adenocarcinoma.
B
arrett's esophagus (BE) is a known risk factor for esophageal adenocarcinoma (EAC), 1 a malignancy with a dismal 5-year survival rate of less than 20%. 2 The risk of EAC increases further if BE is associated with dysplasia. 3, 4 Gastrointestinal societies recommend endoscopic surveillance for BE subjects to enable early detection of dysplasia or carcinoma. [5] [6] [7] This involves endoscopy with 4-quadrant biopsies at 2-cm intervals every 3-5 years for nondysplastic BE (NDBE) and 1-cm intervals every 12 months for low-grade dysplasia (LGD).
Recent studies have estimated a lower risk of EAC in NDBE and LGD than previously estimated. 8 This has led to a debate on the cost effectiveness of current surveillance programs given that most BE subjects have NDBE or LGD. 9, 10 However, the incidence of EAC in the Western world continues to increase, 11 whereas the proportion of patients with EAC who have a known BE diagnosis remains less than 10%. 12 This ostensible discrepancy has raised concerns about the effectiveness of current screening and surveillance programs in reducing EAC incidence. Indeed, although several studies have suggested benefits of surveillance in improving outcomes of those diagnosed with EAC during surveillance, [13] [14] [15] other studies have also reported the lack of any benefit of endoscopic surveillance as it is currently performed.
Moreover, there are data to suggest that physicians do not adhere to current surveillance guidelines particularly in subjects with longer BE segments. 17 Given this mismatch, one has to question the application of current surveillance guideline principles to all patients with BE. More specifically, the concept of stratifying BE subjects with NDBE/LGD based on risk of progression to high-grade dysplasia (HGD)/EAC is appealing. Such stratification would help identify highrisk BE subjects who can be monitored more intensively and/or offered endoscopic eradication therapy. It would also help identify low-risk BE subjects who can be monitored with less frequent or perhaps no surveillance programs, potentially decreasing the surveillance-related health care costs. One such potentially low-risk group is patients with persistent NDBE but the evidence in this regard is not consistent. [18] [19] [20] Previous studies have identified several demographic, clinical, endoscopic, and histologic factors with a potential to predict progression in BE but with conflicting results. Studies have also identified medications protective against progression. A combination of these predictive and protective factors could help build a riskstratification strategy or score for BE subjects. Hence, we aimed to identify the factors that favored progression to or were protective against the development of HGD/EAC in subjects with NDBE/LGD by performing a systematic review and meta-analysis of relevant studies.
Methods
This systematic review was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. 21 It is reported according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. 22 A priori established protocol was followed.
Selection Criteria
To accurately identify the factors that predicted progression in BE, only cohort studies were included in the review. We included studies that met the following inclusion criteria: (1) the study population consisted of BE subjects with NDBE and/or LGD; (2) reported progression to HGD and/or EAC as an outcome; (3) reported factors (both significant and nonsignificant) associated with progression from NDBE/LGD to HGD/EAC as an outcome; and (4) reported measures of association between risk factors and progression as hazard's ratio, relative risk, or odd's ratio (OR) with 95% confidence interval (CI). We excluded studies if (1) study population consisted of BE subjects with baseline HGD; (2) study population was heterogenous but exclusive information on NDBE/LGD subjects could not be extracted; (3) study subjects were treated with endoscopic therapy/surgery; and (4) letters to the editor, editorials, and review articles. If multiple publications were identified from the same population, only data from the most recent comprehensive report were included.
Search Strategy
We conducted a systematic literature search of several databases from inception through May 1, 2016, with the help of an experienced librarian, to identify relevant articles reporting progression to HGD and/or EAC in BE cohorts (NDBE or LGD) under surveillance. The databases included MEDLINE, EMBASE, and Web of Science. The search was restricted to studies on human participants published in English language. Details of the actual search strategy are reported in the attached Supplementary Appendix.
Data Abstraction and Quality Assessment
After identifying relevant studies, 2 authors (R.K., K.R.) independently abstracted data on study character- Two authors (R.K., K.R.) independently assessed the quality of individual studies using the Newcastle-Ottawa Scale for cohort studies. 23 Using the scale, the studies were assigned scores under 3 categories: (1) selection (4 questions), (2) comparability of study groups (2 questions), and (3) ascertainment of the outcome of interest (3 questions). All the questions in NewcastleOttawa Scale received a score of 1, except for comparability of study groups. Studies could score a maximum of 2 points under comparability with separate points for controlling age and/or sex (1 point) and baseline BE characteristics (dysplasia and/or length) (1 point). Studies with a total score of 8, 6-7, and 5 were considered high-, medium-, and low-quality studies, respectively.
Any discrepancies in data abstraction and quality assessment were resolved by jointly referring back to the original articles by 2 authors (R.K., K.R.). 
Outcomes Assessed

Statistical Analysis
Using the random-effects model described by DerSimonian and Laird, 24 we calculated the pooled ORs for each variable of interest and 95% CIs. OR was considered to be equivalent of relative risk and hazard ratio given that incidence of progression to HGD/EAC is relatively low. When reported, adjusted OR from multivariate analysis (accounting for confounding from other variables) was used in the estimation of pooled OR. For specific factors (continuous variables), such as age or BMI when an association was reported in categories, we estimated change in risk per unit exposure, using linear trend meta-analytic statistical methodology. Briefly, when 3 or more categories of a particular risk factor (eg, BMI) were reported, we assigned the midpoint of the cut-points of the category as the dose value; for studies with open-ended categories, we used the lowest and highest reported exposure category from the study to calculate the midpoint. We then calculated the OR for that range of exposure (subtracting the midpoints from the highest risk category with the lowest risk category) to estimate a per-unit OR, after logtransformation. This methodology assumes a linearrelationship between mortality and logarithm of OR of exposure. For studies that reported the relationship between exposure and outcome, both as "per unit" and "per category," we preferred "per unit" analysis for analysis.
There was heterogeneity in the way the studies reported the associations. Although several studies reported results of both univariate and multivariate analysis, [25] [26] [27] [28] [29] [30] [31] [32] others reported only univariate or multivariate analysis results. We performed a sensitivity analysis restricting analysis to studies that performed multivariate analysis adjusted for age and sex to increase the reliability of estimates of associations of lifestyle factors, BE characteristics, and medication use with BE progression. In addition, we also performed a sensitivity analysis restricting analysis to studies with multivariate analysis adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length) to further improve the reliability of estimates of associations of lifestyle factors and medications with BE progression. Inconsistency index (I 2 ) statistic was calculated to estimate the proportion of total variation across studies that were caused by heterogeneity rather than by chance. Values of >50% were suggestive of substantial heterogeneity. If there were 10 studies for any exposure, we assessed for publication bias quantitatively using the Egger regression test. All calculations and graphs were performed using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ).
Results
From a total of 2522 studies identified by our search strategy, 30 independent cohort studies that directly reported OR provided sufficient data to calculate OR between variables of interest and progression to HGD/EAC and were included in the analysis. 9, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Six studies were excluded because of overlapping populations. 3, 18, [44] [45] [46] [47] Four studies were excluded because they reported outcomes in patients with baseline HGD. [48] [49] [50] [51] Together, the 20 included studies reported a total of 1231 events in 74,943 patients. A schematic diagram of study selection is illustrated in Figure 1 . was from Australia. 34 Ten of these studies were multicenter studies. 26 Figure 1) compares the pooled ORs of all investigated predictors of progression. Table 3 and Supplementary   Figure 2 shows results of analysis restricted to studies that reported multivariate analysis adjusted for age and sex. Table 4 and Supplementary Figure 3 shows results of analysis restricted to studies that reported multivariate analysis adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length).
Characteristics of Included Studies
Predictors of Progression
Demographic Factors
Increasing age was associated with increased risk of progression with statistical significance (1 2 studies; OR, 1.027; 95% CI, 1.007-1.046; (Table 3) . On further restricting analysis to the 2 studies that reported multivariate analysis adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length), 28 ,36 smoking was not predictive of progression (Table 4) .
Alcohol use (ever vs never) (6 studies; OR, 1.11; 95% CI, 0.81-1.52; I 2 ¼ 8) 25, 26, 28, 31, 32, 35 did not have a statistically significant association with progression to HGD/EAC. This remained true when the analysis was restricted to studies that reported multivariate analysis adjusted for age and sex (5 studies; Table 3 ) 25, 28, 31, 32, 36 or age, sex, and BE characteristics (baseline dysplasia and/or BE length) (2 studies; Table 4 ). 28, 36 Obesity as measured by BMI (increase per unit) ( did not have a statistically significant association with progression. This remained true when the analysis was restricted to studies that reported multivariate analysis adjusted for age and sex (4 studies; Table 3 ) 25, 31, 32, 36 or age, sex, and BE characteristics (baseline dysplasia and/or BE length) (1 study; Table 4 ). 36 Only 1 study specifically assessed the role of central obesity and reported a numerically but nonsignificantly increased risk of progression in males. 25 Barrett's Esophagus-Related Characteristics BE subjects with LGD had an almost 4-fold increased risk of progression compared with NDBE subjects (11 studies; OR, 4.25; 95% CI, 2.58-7.00). 9, [27] [28] [29] 32, [35] [36] [37] [39] [40] [41] There was substantial heterogeneity among the studies with I 2 ¼ 87. There were differences in effect estimates in subgroup analysis based on study quality. The OR of association between LGD and progression in the 7 highquality studies with BE-LGD subjects was 3.92 (95% CI, 2.20-6.96). 9, 27, 28, 32, [35] [36] [37] We explored sources of heterogeneity by performing subgroup analyses of studies based on patient enrollment period (1970s-1980s vs  1990s-2000s) LGD was predictive of progression with statistical significance when the analysis was restricted to the 6 studies that reported multivariate analysis adjusted for age and sex (Table 3) 9,27-29,32,36 and the 4 studies that reported multivariate analysis adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length) (Table 4) . 9, 28, 29, 36 Increasing BE segment length (per cm) also predicted higher risk of progression (10 studies; OR, 1.25; 95% CI, 1.16-1.36; I 2 ¼ 45). 9, 27, 28, 30, 32, 35, 36, 39, 42, 43 The association remained statistically significant when the analysis was restricted to the 6 studies that reported multivariate analysis adjusted for age and sex (Table 3) 9,27,28,32,36 and the 3 studies that reported multivariate analysis adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length) (Table 4) . 9, 28, 36 Medications PPI use (4 studies; OR, 0.55; 95% CI, 0.32-0.96; I 2 ¼ 51) 26, 31, 35, 38 was protective against progression with statistical significance. On restricting analysis to the 3 studies that reported multivariate analysis adjusted for age and sex, PPI use was not protective against progression. 31, 36, 38 In the 2 studies that adjusted for age, sex, and BE characteristics (baseline dysplasia and/or BE length), the protective effect of PPI was statistically significant. 36, 38 Statin use (3 studies; OR, 0.48; 95% CI, 0.31-0.73; I 2 ¼ 0) 26, 31, 38 was protective against progression with statistical significance. The association remained intact when the analysis was restricted to studies that reported multivariate analysis adjusted for age and sex (3 studies). 31, 36, 38 On further restricting analysis to the 2 studies that reported multivariate analysis adjusted for age, sex and BE characteristics (baseline dysplasia and/or BE length), the protective effect of statin was not statistically significant. 36, 38 NSAIDs (6 studies; OR, 0.72; 95% CI, 0. 
Publication Bias
Quantitative measurement of publication using Egger test was performed for those risk factors for which the meta-analysis included more than 10 studies. There was no evidence of publication bias among the studies reporting progression risk associated with age (P ¼ .27), sex (P ¼ .82), BE length (P ¼ .42), and presence of LGD at baseline (P ¼ .14).
Discussion
Several studies have tried to identify factors that predict malignant progression in BE subjects to risk stratify BE subjects but the results have not been consistent across studies. The current systematic review and meta-analysis identifies demographic factors, lifestyle factors, BE-related characteristics, and medications that had significant associations with the risk of progression to HGD/EAC in BE subjects without dysplasia or with LGD.
Predictors of Progression
The underlying explanation of the effect of increasing age on progression in BE is unclear. It could represent a longer incubation period since the age of onset of BE, which is conceivably a more relevant factor but remains to be defined. The higher progression risk associated with male sex is consistent with the strong male predominance in patients with EAC and may reflect the influence of hormonal factors or central obesity, which is known to be more prevalent in males. 52 The increased progression risk associated with smoking identified in the current study is in line with the established fact that smoking promotes carcinogenesis. 53 Olliver et al 54 demonstrated that smoking specifically inflicts DNA damage in BE mucosa, which in turn likely facilitates progression to EAC. Nicotine is also a lower esophageal sphincter relaxant and smoking per se also increases gastroesophageal reflux. 55 Together, they likely lead to increased exposure of BE mucosa to acid and bile and facilitate neoplastic progression. Notably, of all the risk factors that were identified in this study, smoking was the only reversible factor.
The current study did not find significant association between increasing BMI and BE progression. A recent meta-analysis reported that central adiposity was associated with esophagitis, BE, and EAC. 56 This difference might arise from the fact that central adiposity and not BMI is related to risk of aneuploidy, 17p loss of heterozygosity, and 9p loss of heterozygosity, which could contribute to progression in BE. 57 It is also known that central fat, particularly visceral abdominal fat, is metabolically active releasing adipokines and cytokines that have proinflammatory and proproliferative effects.
In the current study, increasing BE segment length was associated with increased risk of progression in both the overall analysis, which included all studies, and in subgroup analyses of studies that reported multivariate analyses adjusted for age, sex, and BE characteristics. A previous meta-analysis reported that the risk of progression was higher in long segment BE compared with short segment BE. 10 There are 2 main differences between the current meta-analysis and the previous one. The current analysis estimated the risk associated with per centimeter increase in BE segment length rather than compare the risk between long segment BE and short segment BE. The current analysis included subjects with NDBE and LGD, whereas the previous one exclusively included NDBE subjects only.
The risk of progression in subjects with LGD was 4-fold higher compared with subjects with NDBE. These estimates support the current gastrointestinal societies' guidelines to consider endoscopic ablation in BE subjects with LGD in addition to conventional recommendation of surveillance endoscopies every 6-12 months. [5] [6] [7] It has to be noted that the estimation of association between LGD and progression risk in the current meta-analysis was limited by considerable heterogeneity. A previous meta-analysis estimating the risk of progression in LGD was also limited by significant heterogeneity, 58 which suggests that the overall quality of evidence is suboptimal. This is likely a reflection of the known variation in the histologic diagnosis of LGD. Additional factors, such as presence of nodularity, persistent LGD, and confirmation of diagnosis by additional pathologists have been recently reported as factors predicting progression in BE LGD. 59 The current meta-analysis found that use of statin and PPI medications were associated with reduced risk of progression in BE. These results are congruent with previous meta-analyses that individually evaluated the protective role of statins 60 and PPI. 61 However, the number of studies included in the current meta-analysis is less than the previous meta-analyses because we excluded (1) case-control studies, (2) studies including subjects with HGD at baseline, and (3) studies that defined progression as "any dysplasia" rather than HGD or EAC. In the current metaanalysis, the protective effect of NSAIDs was not statistically significant. However, the association was statistically significant when the analysis was restricted to studies that reported multivariate analysis adjusted for age, sex, and BE characteristics. The previous meta-analysis by Zhang et al 62 that reported protective role of NSAIDs was different from the current meta-analysis in several ways. It did not exclude studies performed on subjects with HGD unlike the current review, which includes subjects with baseline NDBE and LGD only. It included cohort and case-control studies unlike the current review, which included only cohort studies.
Strengths and Limitations
The strengths of this analysis include comprehensive and systematic literature search with well-defined inclusion criteria, assessment of association between multiple risk factors (demographic, lifestyle, BE characteristics, and medication use) and malignant progression, rigorous evaluation of study quality, and performance of sensitivity analyses of studies that reported multivariate analysis to account for the effect of confounders (age, sex, baseline BE characteristics).
There are some potential limitations in our study. Several studies included in the analysis did not report multivariate analysis adjusting for known confounders and hence there were smaller number of studies in our sensitivity analyses when limited to the studies that reported adjusted estimates. We were unable to assess the dose/duration-response relationship for such factors as smoking, alcohol, and medications use because of insufficient data in the included studies. The exclusion of case-control studies could also influence the summary estimates of the risk factors.
In summary, the current review investigated a comprehensive list of factors that potentially influence malignant progression in BE. Currently, gastrointestinal societies' guidelines on BE surveillance are solely based on dysplasia grade and do not take into account any of the other risk factors. The current study results could aid in development of a risk score that helps identify highrisk BE subjects with baseline NDBE or LGD, who would benefit from intensive surveillance or endoscopic therapy. Among the factors that were identified to have predictive role, smoking is a modifiable risk factor for cancer prevention in BE subjects.
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